• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Allergan names Daphne Karydas SVP, Global Investor Relations & Strategy

Allergan names Daphne Karydas SVP, Global Investor Relations & Strategy

April 11, 2017
CenterWatch Staff

Allergan, a global biopharmaceutical company, announced that Daphne Karydas will join the company as senior vice president of Global Investor Relations and Strategy, effective April 17, 2017. In this role, Karydas will lead the company's engagement with the investment community, and will work with the company's executive leadership team to develop and execute the company's long-term business strategy. Karydas will report to Tessa Hilado, chief financial officer of Allergan.

"I am delighted to name Daphne to this new role and excited to work with her to continue to enhance our relationships with the investment community, while simultaneously focusing on our long-term growth strategy," said Hilado. "Daphne's outstanding reputation and strong relationships across the financial community coupled with her deep healthcare and industry knowledge provides an excellent fit for this newly created role. She will be a vital leader for our organization as Allergan continues to deliver short- and long-term growth for our shareholders."

"Daphne brings to our team a tremendous mix of financial, healthcare and biopharma industry leadership. She also brings an outstanding perspective on industry and macroeconomic trends that provide the fire power necessary to identify and set strategic objectives that enhance our Growth Pharma leadership position," said Brent Saunders, chairman and chief executive officer of Allergan. "I am excited to work with Daphne as we continue building the most dynamic company in the biopharmaceutical industry."

Karydas has more than 16 years of industry experience as a leading institutional investor and financial analyst in the biopharmaceutical sector, most recently at J.P. Morgan Asset Management. Previously, she was a healthcare Equity Research Analyst and Portfolio Manager at The Boston Company Asset Management, a Bank of New York Mellon company. Before joining The Boston Company, Karydas was a vice president at Goldman Sachs where she worked in the Investment Banking Division as well as Goldman Sachs Asset Management focused on healthcare companies. Earlier in her career, she was a project chemical engineer at Merck & Co. in the Vaccines division where she focused on process development for novel vaccines.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing